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ABSTRACT
There is little empirical evidence to explain why disability declined among the elderly over the past
20 years. In this paper, we explore the role of improved medical care for cardiovascular disease on
health status improvements over time. We show that the incidence of cardiovascular disease
hospitalizations remained relatively constant between 1984 and 1999 at the same time that post-event
survival improved and disability declined. We find that use of appropriate therapies, including
pharmaceuticals such as beta-blockers, aspirin, and ace-inhibitors, and invasive procedures, explains
up to 50% and 70% of the reductions in disability and death over time, respectively. Elderly patients
living in regions with high use of appropriate medical therapies had better health outcomes than
patients living in low-use areas. Finally, we estimate that preventing disability after an acute event
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  Disability among the elderly has declined markedly in the United States in the past two 
decades.  In 1984, 25 percent of the elderly population reported difficulty with activities 
associated with independent living.
1  By 1999, the share had fallen to 20 percent, a decline of 
one-fifth.   
  Although these basic facts are well known, the interpretation of these facts is not clear.  Is 
the reduction in disability a result of improved medical care, individual behavioral changes, or 
environmental modifications that allow the elderly to better function by themselves?  Will the 
trend continue, or is it time limited?  What does the reduction in disability mean for years of 
healthy life and labor force participation?  We explore these issues in this paper. 
  To make progress, we focus on disability caused by a specific set of medical conditions: 
cardiovascular disease.  Focusing on one condition is helpful because it allows us to analyze 
health shocks and their sequellae in some detail.  Cardiovascular disease is a natural condition to 
pick because it is the most common cause of death in the US (and most other developed 
countries), and more is spent on cardiovascular disease than any other condition.  Thus, this is a 
case where medical care could really matter.   
  Our analysis has three parts.  In the first part, we examine basic trends in disability 
associated with cardiovascular disease.  We show that reduced disability for people with 
cardiovascular disease incidents is a major part of reductions in overall disability, accounting for 
between one-fifth and one-third of the total reduction in disability.  The second part of the paper 
considers the role of advances in medical care in reducing disability from cardiovascular disease.  
We show that medical technology in the treatment of cardiovascular disease is a major factor in 
reduced disability.  We estimate that use of recommended treatments for heart attacks, including 
                                                 
1  The data are from the National Long-Term Care Survey, a survey we describe later and use in this paper.   4 
prescriptions of beta-blockers, aspirin and ace-inhibitors at discharge, as well as use of 
reperfusion and other surgical procedures increased the probability that elderly patients survive 
an acute cardiovascular event in a non-disabled state by 13 to 22 percent between 1984 and 
1994. The third part of the paper considers the long-run health and financial impacts of improved 
care for people with cardiovascular disease.   
 
I.  Background on Cardiovascular Disease   
Cardiovascular diseases are diseases of the heart and blood vessels which carry oxygen to 
the body’s major organs.  Ischemic heart disease is the most common manifestation of 
cardiovascular disease.  When the arteries supplying blood to the heart become occluded, the 
heart does not get enough oxygen.  Like any muscle, oxygen is essential for the heart’s 
performance.  Constriction of the coronary arteries will result in chest pain on exertion, or 
perhaps at rest.  A person with such constriction might be unable to engage in activities such as 
walking for a prolonged period (for example, to get to a grocery store) or engaging in light or 
heavy housework (cleaning, cooking, etc.)   
A blockage of the arteries to some or all of the heart is termed a myocardial infarction, or 
heart attack.  The equivalent in other extremities, especially the legs, is termed peripheral 
vascular disease.  Heart attacks can be fatal, and can lead to substantial disability if survived.  A 
person who survives a heart attack might be unable to shop or cook, might have difficulty 
walking up stairs or entering a raised bathtub, and might have difficulty keeping house.  
Peripheral vascular disease can lead to the same types of impairments. 
Medical advance has made tremendous strides in preventing and treating coronary events.  
Several risk factors for heart disease are well known.  Traditional risk factors include smoking;   5 
hypertension or high blood pressure; high cholesterol; obesity; family history, age and diabetes.  
Since the early 1970s, standard recommendations for people at risk have been behavioral 
changes (stop smoking, reduce weight, cut back on fat intake, and exercise) combined with 
medical therapy (antihypertensive medication, and more recently cholesterol-reducing 
medications).  (Cutler and Kadiyala 2003) show significant reductions in the incidence of heart 
disease over time attributable to reductions in these risk factors, especially reduced smoking and 
better blood pressure control.   
There have also been technological changes in the treatment available for people with 
severe heart disease.  Bed rest was once standard therapy for people with heart attacks.  Today, 
therapy for a heart attack, and often heart disease in earlier stages of progression, generally starts 
with drugs such as aspirin help dissolve clots and restore blood flow to the heart.  Beta-blockers 
are also given to reduce the workload of the heart, and thus reduce the demand for oxygen. In 
addition, ace-inhibitors are prescribed to help reduce the workload of the heart by lowering blood 
pressure Statins are prescribed to help process and break down cholesterol in the arteries 
(American Heart Association 2006).  
Finally, there have been significant advances in acute care and invasive surgical 
procedures for treating coronary blockage.  Thrombolytics are a class of drugs that may be used 
to help dissolve the clot. Percutaneous coronary intervention (PCI) is used to clear out blockages 
of the coronary arteries.  These procedures are now frequently accompanied by use of a stent to 
keep the occluded artery open.  A more invasive option is coronary artery bypass grafting 
(abbreviated CABG, and pronounced like the vegetable).   
Each of these technologies has been shown to increase survival after a heart attack among 
patients without contraindications for treatment (Krumholz, Radford et al. 1995; Hennekens,   6 
Albert et al. 1996; Krumholz, Radford et al. 1996; Soumerai, McLaughlin et al. 1997; Gottlieb, 
McCarter et al. 1998; Krumholz, Radford et al. 1998; Freemantle, Cleland et al. 1999; Shlipak, 
Browner et al. 2001; Braunwald, Antman et al. 2002; Antman, Anbe et al. 2004; Vitagliano, 
Curtis et al. 2004; Stukel, Lucas et al. 2005).  They have an ambiguous effect on disability, 
however, with the increase in survival among those with serious heart damage possibly offsetting 
the improved health among traditional survivors (Crimmins, Saito et al. 1989; Crimmins, 
Hayward et al. 1994; Waidmann, Bound et al. 1995).  
Cerebrovascular disease, or stroke, is the second major form of cardiovascular disease.  
Ischemic strokes are the most common type of stroke, and are similar to heart disease: an artery 
in the brain becomes blocked, and a part of the brain is denied oxygen.  Disability is quite 
common after a stroke, particularly among the elderly (Pohjasvaara, Erkinjuntti et al. 1997; 
Prencipe, Ferretti et al. 1997; Zhu, Fratiglioni et al. 1998). Recent studies report that 39% to 54% 
of stroke survivors are disabled 3-months after the stroke (Henon, Godefroy et al. 1995; Zhu, 
Fratiglioni et al. 1998; Glader, Stegmayr et al. 2003). The high level of disability can persist 
among survivors. One study found 37% of stroke survivors were disabled one year after the 
event (Appelros, Nydevik et al. 2003). In addition, stroke is associated with increased odds of 
cognitive impairment, both with and without dementia (Pohjasvaara, Erkinjuntti et al. 1997; 
Prencipe, Ferretti et al. 1997; Zhu, Fratiglioni et al. 1998).  
Thrombolytic medication might be given after a stroke, but the benefit is far less certain 
than in heart disease. Clinical trials show that thrombolytics are effective only if given in the first 
three hours after an acute event (Group 1995; Clark, Wissman et al. 1999; Adams, Adams et al. 
2005).  Revascularization procedures such as carotid endarterectomy may be performed in 
patients with certain types of stroke, including transient ischemic attacks, after the patients have   7 
recovered from the acute phase of the stroke.  A small share of strokes are hemorrhagic strokes, 
where a blood vessel bursts and there is bleeding in the skull.  Little therapy is generally 
available in such cases, and death is common.   
Heart failure and arrhythmias are other types of cardiovascular disease that cause 
substantial morbidity and mortality among the elderly. Heart failure occurs when the heart’s 
ability to pump blood is impaired. Patients may experience breathlessness and fatigue that makes 
it difficult to keep up usual activities, fluid retention and edema, coughing, memory loss and 
heart palpitations. An arrhythmia is an irregular heartbeat that can cause the heart to pump blood 
less effectively. Patients with heart failure and/or arrhythmias may also be at substantial risk for 
stroke and other complications (American Heart Association 2006). Treatment for heart failure 
includes ace-inhibitors or angiotensin II receptor blockers, beta-blockers, and diuretics. 
Appropriate patients may also undergo valve replacement surgery or other revascularization. 
Patients with arrhythmias often receive pacemakers and occasionally receive implantable 
cardioverter defibrillators along with antiarrhythmic drugs and blood thinners.  
Other cardiovascular diseases, generally with smaller prevalence, include rheumatic heart 
disease, aneurysms, acute pulmonary heart disease, other diseases of the endocardium, capillary 
diseases, and problems with veins (e.g. varicose veins).  
 
II.  The Importance of Cardiovascular Disease for Reductions in Disability  
Like every multidimensional concept, there is no perfect measure of disability.  We 
follow the lead of most researchers in measuring disability as the presence of impairments in 
Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (IADLs). Our data 
source, the National Long-Term Care Survey of 1984-1999 – abbreviated NLTCS – includes   8 
information on 6 ADL measures: eating, getting in or out of bed, walking around inside, 
dressing, bathing, and getting to the toilet or using the toilet.  Questions are also asked about 8 
IADL measures: doing light housework, laundry, preparing meals, shopping for groceries, 
getting around outside, managing money, taking medications and making telephone calls.     
The NLTCS is a nationally-representative longitudinal survey of the health and disability 
profile population aged 65 and over. The first NLTCS survey wave was conducted in 1982 and 
subsequent surveys were administered in 1984, 1989, 1994 and 1999. Each survey wave began 
with a screener that collected information on whether the respondent reported difficulty 
conducting the 6 ADLs and 8 IADLs without help (i.e. help from another person or special 
equipment), and whether any difficulty had lasted or was expected to last at least 3 months. The 
screener also collected demographic information on marital status, race and age.  
Respondents who reported difficulty with any ADLs or IADLs for at least 3 months on 
the screener were asked to complete a detailed survey. Disability status was determined by 
responses to questions about use of help and inability to conduct the ADLs and IADLs on the 
detailed survey. Sampling and weighting issues are described fully elsewhere (Manton, Corder et 
al. 1993; Manton, Corder et al. 1997; Manton, Stallard et al. 1997; Singer and Manton 1998; 
Manton and Gu 2001).  
We obtained Medicare-linked data for all NLTCS participants, including data on date of 
death from the denominator files. We used inpatient claims for all analyses, because Medicare 
claims files for part B and other non-hospital services were incomplete prior to 1991. We also 
obtained data on zip code of residence at the most recent interview for all NLTCS survey 
respondents.     9 
Basic data on disability among the elderly population is shown in Figure 1.  For reasons 
that will become clear briefly, we report disability for the population that is aged 70 and older in 
each of three years: 1989, 1994, and 1999.  The share of the elderly population that is disabled 
declined markedly in the decade of the 1990s.  The cumulative decline was 6.3 percentage 
points, or 2.1 percent per year.   
To examine the role of cardiovascular disease in explaining this reduction in disability, 
we form a population sample likely affected by the condition.  We start by looking at the 
population aged 70 and older in the 1989, 1994, and 1999 surveys.  For each of these cohorts, we 
group all hospitalizations over the preceding 5 years into one of 32 categories (the five year look 
back is the reason for the restriction to people over 70).  These categories were designed to pick 
up relatively homogenous clinical conditions that would be predictive of disability.  The set of 32 
categories is shown in Table 1, along with the rate of disability for people hospitalized with each 
condition from the 1989 survey cohort.  The relevant categories for cardiovascular disease are 
stroke, hypertension, ischemic heart disease, heart failure and arrhythmia, peripheral vascular 
disease, and other circulatory diseases.
2 
Figure 2 reports the share of people with a hospitalization for any of these conditions.  
Twenty-two percent of people were admitted to a hospital with some cardiovascular disease.  
Ischemic heart disease is the most common admission, accounting for 8 percent of admissions.  
Stroke and heart failure are also common, as are other circulatory diseases.  Admissions for 
peripheral vascular disease and hypertension are much less common. 
                                                 
2 ICD-9 codes are as follows:  stroke:  362.34, 430, 431, 432.9, 433-436; hypertension: 401-402, 405, 437.0, 437.9; 
ischemic heart disease; 4.10-4.14, 429.5-429.7, excluding 414.11 and 414.19; heart failure and arrhythmia:  425, 
427.1, 427.3-427.5, 428, 429.1, 429.3; peripheral vascular disease: 440, 442, 443.0 - 443.1, 443.8 - 443.9, 444, 446, 
447.0-447.5, 447.8-447.9, 451, 453.1; and circulatory diseases: 391-400, 406-409, 414.11, 414.19, 415-424, 426, 
427.2, 427.6, 427.8, 427.9, 429.2, 429.4, 429.8, 429.9, 432.1 – 432.8, 437.1 – 437.8, 439, 441, 443.2, 445, 447.6, 
448 – 450, 452 – 453.0, 453.2 – 459, 786.5, V717.   10 
A person who had a hospital admission for cardiovascular disease and is disabled may or 
may not have been disabled because of that condition.  The NLTCS does not reliably determine 
the precise condition that leads to each disability (Landrum and Stewart 2006).  We make two 
alternative assumptions about the probability of being disabled by cardiovascular disease.  The 
first assumption, a less restrictive assumption, labels someone as disabled from cardiovascular 
disease if they were admitted to a hospital with cardiovascular disease in the previous five years.  
The more restrictive assumption subsets this group to those for whom the most disabling 
condition was cardiovascular disease
3 – where the list of conditions by disability status is 
reported in Table 1.  Thus, a person who had a stroke and hip fracture would be termed disabled 
because of cardiovascular disease by the first measure, but not by the second measure.  
Fortunately, our results are very similar regardless of the definition used 
Figure 3 shows the probability of being disabled by cardiovascular disease.  Using the 
less restrictive measure, the decline in disability is 1.4 percentage points, or 22 percent of the 6.3 
percentage point total reduction in disability.  Using the more restrictive measure, the decline is 
0.9 percentage points, or 14 percent of the total decline.  In each case, cardiovascular disease is a 
substantial share of the total decline. 
As noted above, the conclusion that cardiovascular disease is a substantial share of 
disability decline contradicts an earlier literature that suggested that ‘marginal survivors’ 
contribute to an increase in disability.  If more people survive strokes, the argument went, the 
share of the elderly with disabilities would rise.  The finding of a reduction in disability suggests, 
in contrast, two other hypotheses: either fewer people are suffering cardiovascular disease 
events; or those who have always survived such events are less disabled now than they were 
                                                 
3 Note even this more restrictive assumption may underestimate the importance of disabling diseases, such as 
arthritis or dementia, that are not common causes of hospitalizations. 
   11 
formerly, i.e. the incidence of disability among cardiovascular disease patients is falling.  These 
possible effects are demonstrated in equation (1): 
 
(1)  Pr[Disabled from CVD]  =  Pr[Had CVD Incident]  *  Pr[Survive | Had Event]   *  
        Pr[Disabled | Had Event, Survival] 
 
The first term on the right hand side is the incidence of events.  The second term is the survival 
rate, and the third term is the health effect among survivors.  The change in disability rates is 
arithmetically related to the change in one or more of these factors.
4  The marginal survivors 
theory focuses on the second term: the change in the probability of survival after an acute event, 
i.e. as more patients survive acute events, the pool of people at risk of disability expands.  The 
other theories focus on the first and third terms, i.e. either reduced incidence of disease or better 
health among survivors. 
Table 2 shows cardiovascular disease event probabilities, survival rates, and conditional 
disability rates for each of our three time periods.  To measure the cardiovascular disease event 
rate, we consider the population surveyed at the beginning of the 5-year interval, and look at 
events in those five years.  For example, the cardiovascular disease event rate for the 1989 cohort 
is the share of the population aged 65 and older in 1984 that had a cardiovascular disease 
hospital admission in the subsequent five years.
5 
                                                 
4  There are covariance terms as well, but these are generally small. 
5  Were the NLTCS a fixed panel survey, the sample of people at the starting year (for example 1984) would be only 
those for whom the disability status is known five years later plus those who died in the interim.  The NLTCS did 
not interview the entire sample every year, however, so some people are lost to follow-up.  To generate a nationally 
representative sample, we analyzed only those people whose health and mortality status were known at follow-up 
for each survey year, and re-weighted the sample weights to reflect the age-sex distribution of all respondents to the 
1999 survey.    12 
The first row shows that the share of people who had a hospitalization for cardiovascular 
disease was relatively constant over the time period, at about 26 percent.  This is somewhat 
surprising given the reduction in event rates noted in other surveys such as the Framingham 
Heart Study (Sytkowski, D' Agostino et al. 1996) and the Minnesota Heart Survey (McGovern, 
Pankow et al. 1996; McGovern, Jacobs et al. 2001). It may be that some of the admissions 
among the later cohorts in our study were done explicitly to perform surgical operations such as 
angioplasty or bypass surgery, and thus contribute to an increased reporting of cardiovascular 
disease. However, another recent U.S. study of subjects aged 35 to 74 reported little change in 
the incidence of first myocardial infarction between 1987 and 1994 (Rosamond, Chambless et al. 
1998).  Alternatively, it may be that less severe cases of these conditions are being diagnosed 
over time.
6   
In addition, the Framingham and Minnesota studies included patients younger than 65, 
and results from these studies may have been driven by a decline in heart disease among the 
younger population. A Finnish study of coronary heart disease between 1978-1980 and 2000-
2001 reported decreased prevalence of coronary heart disease among men and women aged 45 to 
64 years, no change in prevalence among men and women aged 65 to 74 and increased incidence 
among people aged 75 and over (Kattainen, A. et al. 2004). Our results may reflect similar trends 
in age-related incidence of heart disease.  
The second row of the table shows a significant increase in the survival rate to the next 
survey for people admitted to a hospital with cardiovascular disease.  The survival rate increased 
by 4.3 percentage points, or about 7.5 percent.  By itself, this would have led to an increase in 
disability from cardiovascular disease.  This effect is overwhelmed, however, by the substantial 
                                                 
6 Clinical trials published in 1996 showed that a blood test for troponin, a protein released from damaged heart 
tissue, can be used to diagnose heart attacks.  This likely led to greater diagnosis of smaller heart attacks, and may 
also have led to increased hospitalizations, depending on how frequently these patients were previously admitted.   13 
reduction in disability among survivors, shown in the third row of the table.  The share of CVD 
survivors who are disabled fell from 48 percent in 1989 to 39 percent in 1999, a 19 percent 
reduction.  It is this massive reduction in event-specific disability that needs to be explained. 
 
III.  Medical Care and CVD-Related Disability 
Before estimating formal statistical models to address the role of medical care in reduced 
CVD-related disability, we consider a less structural analysis of the role of medical care.  
Specifically, we look at how disability changed in the period shortly after the cardiovascular 
disease event relative to the period several years later.  If the reduction in disability followed 
immediately after the cardiovascular event, it strongly suggests that medical treatment of the 
acute event was the major factor responsible for the reduction in disability.  A disability 
reduction further out in time might be attributable to medical intervention, but other factors, such 
as better coping with limitations due to improved environmental factors, could be important as 
well.   
Figure 4 shows the change in disability rates for people whose cardiovascular disease 
event happened within 6 months of the survey, by type of event. The rate of disability declined 
from 1984-1989 cohort to the 1994-1999 cohort for people with hospitalizations for ischemic 
heart disease, heart failure and arrhythmia, stroke and other cardiovascular disease. For heart 
failure and arrhythmia patients as well as other cardiovascular diseases, there were increases in 
the disability rate from the 1984-1989 to 1989-1994 cohorts that need further explanation
7. 
Overall, though, it seems that medical advances could have some role in this change decline in 
disability between 1984-1989 and 1994-1999.  
                                                 
7 For example, the average severity of heart failure hospitalizations may have increased over time if physicians and 
patients were better able to manage heart failure in the outpatient setting.    14 
 
Empirical Methodology 
To examine the role of medical technology changes in event-related reductions in 
disability more formally, we estimate regression models for the health of patients who have been 
admitted to a hospital with cardiovascular disease.  Our sample is formed from each of the three 
cohorts.  We select people who were admitted to a hospital with cardiovascular disease in the 
1984-89 period, the 1989-94 period, and the 1994-99 period.  In each case, the sample includes 
all people for whom we know health status at the beginning and end of the 5-year period.  There 
are three possible health states at the end of each period, i.e. at the time of follow-up survey: 
dead; alive and non-disabled; and alive and disabled.  We denote these possible outcomes with 
the subscript k.   
Consider for the moment a single measure of medical treatments, which we wish to relate 
to the change in disability.  For concreteness, assume that the variable is the share of people in an 
area who receive a surgical procedure that has been shown to be effective in improving health for 
people with that condition.  The treatment rate for area j in time period t is denoted Tj,t.  We 
model the probability that person i will be in health state k using a multinomial logit formulation:  
 
(2)   Pr[health state k]i,j,t   = 
exp(Xi,t ￿k + ￿k Tj,t  +   ￿k cohortt) / (1+exp(￿ Xi,t ￿l + ￿l Tj,t  +  ￿l cohortt) 
 
where Xi,t is a set of demographic variables, ￿k’s are the coefficient of interest.  Our demographic 
variables include age/sex (five year age groups differentiated by gender); dummy variables for 
other cardiovascular disease hospitalizations, a modified Charlson index (i.e. without   15 
cardiovascular disease diagnoses) (Deyo, Cherkin et al. 1992) marital status at the beginning of 
the five year window (married; widowed; and divorced/separated); and race (white and non-
white).   
One issue that comes up in any estimation involving an equation like (2) is the issue of 
causality.  If treatments are not randomly assigned, estimates of ￿ will be biased.  We address 
this issue in several ways.  The most important is to use area-level variation in treatments, rather 
than individual-level variation.  Whether any individual receives a treatment is dependent on the 
physician’s perception of that patient’s underlying health.  If the underlying severity of disease is 
relatively constant across areas and over time, however, variations in treatment at the area level 
will be good markers for exogenous changes in the use of medical care. As is standard in the 
literature (O' Connor, Quinton et al. 1999; Fisher, Wennberg et al. 2003; Fisher, Wennberg et al. 
2003; Stukel, Lucas et al. 2005), we group individuals into areas based on the Hospital Referral 
Region (HRR) they live in.  HRRs are groups of zip codes where the bulk of patients go to the 
same set of hospitals and include at least one hospital with a tertiary cardiovascular or 
neurological surgical center.  For example, the HRR for Chicago includes zip codes 60601-
60712; within this area, the vast majority of people who are hospitalized get admitted to a 
hospital in that region. 
To facilitate interpretation of the results, we center all demographic and HRR-level 
covariates. This allows us to interpret the coefficients on the survey year dummy variables as the 
change in the log-odds of disability and death relative to being alive and non-disabled for the 
average person living in the average area across survey cohorts. We also begin our analyses with 
models that include only survey year dummy variables and demographic and health status 
covariates. We compare these models to models that include cardiovascular disease medical   16 
treatments to evaluate whether including treatment in the models changes the association 
between survey year and the likelihood of death and disability for the average patient.  
 
Measures of Medical Treatment 
We use several measures of medical care to predict disability.  The first variable is the 
share of people who receive surgical interventions.  To define relevant procedures, we identify 
treatments for each specific diagnosis that the medical literature has identified as being 
efficacious (generally in reducing mortality) for at least some subsets of patients with that 
diagnosis.  These procedures are detailed in table 3.  For hypertension, there are no generally 
accepted surgical therapies. There are one or more therapies for the other conditions, of which 
the most common appropriate procedures are “other operations on the heart and blood vessels” 
(CPT code 37), which includes PCI (angioplasty), heart replacement procedures and insertion of 
pace-makers, and “incision, excision and occlusion of vessels” (CPT code 38), which includes 
endarterectomies.  CABG procedures for ischemic heart disease patients are coded under CPT 
code 36, “Operations on vessels of heart”. 
Table 4 shows the average rate of procedure use over time across hospital referral 
regions, for all cardiovascular disease patients and by specific conditions.  In the 1984-89 cohort, 
the average procedure rate was only 21 percent across regions. The average procedure rate was 
highest for other circulatory diseases (30%), followed by ischemic heart disease (23%), stroke 
(13%) and heart failure and arrhythmia (11.3%).   By 1994-1999, the average procedure rate for 
all patients across all regions increased to 34%. The average procedure rate for ischemic heart 
disease patients jumped to 48%. Average procedure rates increased to 43% for other circulatory   17 
diseases, 25% for stroke and 14.2% for heart failure and arrhythmia. These increases reflect the 
greater belief among physicians about the efficacy of therapy, and advances in the therapy itself.
8   
Our other measures of medical technology involve use of pharmaceuticals for patients 
with acute myocardial infarction.  As noted in the previous section, these pharmaceuticals have 
been shown to improve survival, although the overall effect of pharmaceutical treatment on both 
improved survival and disability in the elderly has not been well-established. Randomized 
studies comparing various treatments for ischemic heart disease on functional status and quality 
of life reported improvements for most outcome measures for both medical and surgical 
therapies (Rogers, Coggin et al. 1990; Strauss, Fortin et al. 1995; Hlatky, Rogers et al. 1997; 
Pocock, Henderson et al. 2000; Borkon, Muehlebach et al. 2002; Pfisterer, Buser et al. 2003). . 
However, most of these studies included patients under age 65 who may be more likely to 
improve than elderly patients (Rogers, Coggin et al. 1990; Strauss, Fortin et al. 1995; Hlatky, 
Rogers et al. 1997; Pocock, Henderson et al. 2000; Borkon, Muehlebach et al. 2002). A recent 
trial comparing medical and surgical management of elderly patients with coronary artery 
disease reported improved quality of life at one year for both treatment arms (Pfisterer, Buser et 
al. 2003), suggesting that treatment likely reduces disability in the elderly population. However, 
no studies to date have estimated the effect of increased use of appropriate pharmaceutical 
treatments over time on disability rates in the elderly population.  
Pharmaceutical use is not captured in Medicare claims, since Medicare does not pay more 
for use of pharmaceuticals.  Thus, we do not have time series data on the use of pharmaceuticals 
by area.  We do have a snapshot of data on pharmaceutical use, taken from a survey of medical 
records in the mid-1990s.  The cooperative Cardiovascular Project (CCP) abstracted medical 
                                                 
8  For example, catheters used in surgery have improved, and stents were developed for use in angioplasty in the mid 
1990s. 
   18 
record data on 186,800 Medicare patients hospitalized for an AMI between February 1994 and 
July 1995 including data on appropriateness for and receipt of guideline recommended 
treatments (Marciniak, Ellerbeck et al. 1998). 
Use among patients most suited for treatment ranged from 51% for beta-blockers in the 
immediate post-myocardial infarction treatment to 76% for aspirin. Average utilization rates for 
the mid-1990s are shown in table 4.  Researchers at Dartmouth have calculated the average use 
rate of each of these pharmaceuticals at the HRR level, which we employ in our analysis 
(O' Connor, Quinton et al. 1999).   
While not known at the area level, use of these pharmaceuticals did increase during our 
study timeframe. Reported use of aspirin for heart attack patients in 1985 and 1995 was 30% and 
75%, respectively, and over the same time, use of beta blockers was 48% and 50%, 
thrombolytics was 9% and 31%, and ace-inhibitors was 0% and 21%, respectively (Heidenreich 
and McClellan 2001). The change in ace-inhibitors use from this study was based only on 
changes in the Worcester, Massachusetts area and may not reflect changes in use nationally. 
For patients with heart failure and stroke we employed published data on state-wide use 
of evaluation of ejection fraction (heart failure) and use of warfarin for patients with atrial 
fibrillation and prescription of antithrombotics at discharge for patients with acute stroke or 
transient ischemic attack (stroke) from 2000-2001 (Jencks, Huff et al. 2003).   
The lack of time series data on pharmaceutical use at the area level requires us to make 
one change in the analysis.  Equation (2) assumes that the procedure has the same effectiveness 
over time. Since use of pharmaceuticals increased over time, we would expect that the 
coefficient on pharmaceutical use would be greater for the 1994-99 cohort than for the 1984-89   19 
cohort; more patients, after all, would have been treated with the technology. To account for this 
phenomenon, we interact each treatment variable with the survey year dummy variables.   
From our models, we estimate the likelihood of being disabled, dead and alive and non-
disabled at follow-up if all respondents lived in HRRs that provided relevant procedures and 
pharmaceuticals at the 10
th and 90
th percentiles of care, holding all other covariates constant. We 
develop separate estimations for relevant procedures and pharmaceuticals to better understand 
the effect of each treatment type on changes in death and disability over time. 
 
Estimation Results 
Table 5 shows demographic characteristics of our cohort by year of baseline survey. The 
proportion of respondents disabled at baseline declined over time, from 32% in 1984 to 25.9% in 
1994. This 6 percentage point decline in disability at baseline is consistent with other analyses 
using the NLTCS (Manton and Gu 2001). In addition, there was a slight increase in the mean 
modified Charlson index score from 0.94 in 1984 to 1.07 in 1994.  
Coefficients and standard errors from our estimation results are shown in tables 6-10 for 
models with all cvd patients, ischemic heart disease patients, stroke patients, heart failure 
patients and other circulatory disease patients. Each table includes a model with only survey year 
and demographic characteristics as well as a model with area-level relevant procedures, 
appropriate pharmaceutical use and interactions between year and time-invariant treatment 
covariates.  
 
All-CVD    20 
In the all-cvd models, the average respondent from the 1994 survey was significantly less 
likely to be disabled and dead compared to the average respondent to the 1984 survey, when 
adjusting for only demographic and health status covariates (Table 6). When we include 
treatments covariates, the average respondent living in an area with average treatment rates in the 
1994 survey was significantly less likely to experience disability and death at follow-up survey 
compared to the average respondent in an average area in 1984, but inclusion of treatment 
covariates moderated the associations. In particular, area-level use of treatments explains 
approximately 3.5% and 29% of the difference in disability and death outcomes, respectively, 
between the 1994 and 1984 cohorts. Relevant procedures were significantly associated with a 
decreased likelihood of death (p= 0.044), but not disability (p=0.756), while all AMI treatments 
together were significantly associated with disability (p= 0.001) and death (p=0.020).  
Predicted event rates for all cvd patients in areas at the 10
th and 90
th percentiles are shown 
in Figures 5 and 6. For relevant procedures, the probability of death is lower at all time points for 
90
th percentile areas, and due to increasing rates of procedure use, it decreases faster for the 90
th 
compared to 10
th percentile over time. When examining time invariant AMI treatment variables 
together, we find that the probability of disability declined 6 percentage points from 28% in 1984 
to 22% in 1994 for the 90
th percentile and increased approximately 3 percentage points from 
23% to 26% in 10
th percentile areas.  
 
Ischemic Heart Disease 
As described in more detail in (Stewart, Landrum et al. 2006), treatment covariates 
explain between 50 and 70% of the association between disability and death over time in the   21 
IHD cohort.  Relevant procedures were significantly associated with death, but not disability, and 
pharmaceutical care was significantly associated with disability but not death.  
 
Stroke 
Stroke patients in 1994 were significantly less likely to experience disability and death 
compared to patients in the 1984 survey in the model with only demographic and health status 
covariates (Table 7). Including treatment covariates explains approximately 42% and 23% of the 
association between 1994 survey year and disability and death, respectively. The coefficient on 
1994 survey year for disability is not statistically significant in the model with treatments, 
suggesting that in areas with average levels of treatment there were no significant declines in 
disability. The coefficient on 1994 survey year for death remains statistically significant, 
suggesting that additional factors are important in explaining the decreased probability of death 
in 1994 relative to 1984.  
Use of relevant procedures for stroke patients is significantly associated with lower 
likelihood of disability (p = 0.010), but not with death (p=0.157). Use of AMI treatments 
measured at the HRR-level from the CCP data and increased use of warfarin and anti-
thrombolytics measured at the state level are together significantly associated with death (p = 
0.001) but not disability (p=0.175). These results are apparent in predicted outcome rates 
displayed in Figures 7 and 8.  The predicted probability of disability for stroke patients in 90
th 
percentile areas of relevant procedures falls from 29% in 1984 to 25% in 1994 (?) and the 
probability of disability in 10
th percentile areas rises from 33% in 1984 to 36% in 1989 and back 
to 33% in 1994 (Figure 7). In areas at the 90
th percentile for AMI and stroke treatments, the 
probability of death declines from 48% in 1984 to 35% in 1989 and then increases to 40% by   22 
1994 (Figure 8). The trend is opposite in 10
th percentile areas, with the probability of death 
increasing from 43% in 1984 to 51% by 1989 and then decreasing to 42% by 1994.  
 
Heart Failure and Arrhythmia  
Table 8 shows that the heart failure and arrhythmia patients in 1994 were significantly 
less likely to die by follow-up compared to patients in 1984 in the model with only demographic 
and health status covariates. Including treatment covariates strengthens the association between 
survey year and death, i.e. the average respondent in the average area is even less likely to die in 
1994 compared to 1984. Relevant procedures for heart failure and arrhythmia are not associated 
with either disability (p = 0.903) or death (p = 0.574). Use of AMI treatments and evaluation of 
ejection fraction are significantly associated with disability (p=0.043) but not death (p=0.087). 
As expected based on estimation results, there is little difference in the probability of death and 
disability between 10
th and 90
th percentile areas of relevant procedures (Figure 9). In 
examination of the AMI and heart failure treatments (Figure 11), the probability of disability is 
higher in 90
th percentile areas in 1984 and 1989 compared to 10
th percentile areas. By 1994, the 
probability of disability is much lower in the 90
th percentile areas (19%) compared to the 10
th 
percentile (26%).   
 
Other Circulatory Diseases 
In the model with demographic and health characteristics, circulatory disease patients in 
the 1994 survey were significantly less likely to be disabled and dead at follow-up compared to 
the 1984 survey (Table 9). When we include treatment covariates, we explain approximately 
18% of the association between 1994 survey year and death, and the 1994 survey year coefficient   23 
on death is no longer statistically significant. The 1994 survey year coefficient on disability 
becomes more negative with the inclusion of treatment variables, i.e. -0.38 vs. -0.37, and remains 
statistically significant. Relevant procedures are not associated with either disability or death in 
this model. AMI treatments are associated with disability (p=0.044), but not with death 
(p=0.146). Predicted outcomes rates by AMI treatments show that the probability of disability 
declines by 13 percentage points in 90
th percentile areas from 32% to 19% and increases by 8 
percentage points from 25% to 33% in 10
th percentile areas (Figure 12).  
 
IV.  Interpreting the Results 
Use of effective treatments contributed to the decline in disability and death among 
cardiovascular disease patients. The association between treatment use and reduced disability 
and death was strongest in the ischemic heart disease model, explaining over half of the decline 
in disability for the 1994 cohort and 65-70% of the decline in mortality for the 1989 and 1994 
cohorts. With the exception of the stroke model, use of AMI treatments was significantly 
associated with declining disability. In the all-CVD and stroke models, AMI treatments were 
significantly associated with reductions in mortality. Increased use of relevant procedures 
resulted in lowered disability among stroke patients as well as lowered death in the all-cvd and 
ischemic heart disease models.   
Improved medical treatment after an acute cardiovascular event resulted in improved 
survival and reductions in disability. It may also affect medical spending.  While we cannot do a 
complete evaluation of the impact of these changes, we can provide some information.  We 
begin with the change in quality-adjusted life expectancy.  To consider how reductions in 
disability in one year translate into long-term changes in quality-adjusted life expectancy, we   24 
estimate regression models for future survival and disability status as a function of disability in a 
base year.  For a cohort in year t, we estimate linear probability models of the form: 
 
(3)  Pr[Alive in year t+k]i =   Xi,t ￿ + ￿ Disabilityi,t  +   ei,t 
 
The coefficient ￿ indicates how changes in disability in year t affect long-term health 
outcomes.  Xi,t is a set of demographic and health status variables. The identifying assumption in 
equation (3) is that people who are not disabled because of medical treatment are subsequently 
equivalent in their health to those who never had an incident.  This may or may not be the case.  
If this is not true, and survivors of events are less healthy, conditional on disability status, we 
will overstate the benefits of reductions in disability.  Thus, one should properly view these 
estimates as an upper bound on the impact of medical interventions to reduce disability. 
Figure 13 shows the survival rate by year, conditional on disability status in the base 
survey year.  We report the results for the 10 years after the survey for the 1989 cohort, and the 
five years after the survey for the 1994 cohort due to data limitations on long-term follow-up. 
Not surprisingly, survival for the disabled is below that for the non-disabled, by a large margin.  
The difference is about 20 percentage points, and remains at that level throughout the decade.  
To forecast mortality beyond the 10 year observation window, we assume that the mortality 
hazard estimated in 1997-99 prevails in all subsequent years.  Making this assumption, we 
estimate that those not disabled in 1989 have an average life expectancy of 7.8 years while those 
disabled in 1989 were expected to live only another 5.1 years on average (Table 11).   
The above calculation, does not account for the difference in subsequent disability in the 
next decade.  Table 10 shows the disability rate for the 1989 cohort in the 1994 and 1999   25 
surveys, and the disability rate for the 1994 cohort in 1999.  In each case, we condition disability 
status on being alive at the end date.  Seventy-nine percent of people who were disabled in 1989 
and still alive in 1994 were also disabled in 1994, compared to 31 percent of those not disabled 
in 1989.  This pattern repeats itself in 1999, and is true for the 1994 cohort as well.   
To estimate quality-adjusted life expectancy, we interpolate disability rates between 1989 
and 1994, and 1994 and 1999.  In each case, we assume that disability rates change at a common 
rate each year of the interval.  We also extrapolate disability rates after 1999 using the annual 
change between 1994 and 1999.  As a rough approximation, we assume that 1 year in a disabled 
state is equivalent to 0.5 quality-adjusted life years. 
As the second row of table 11 shows, quality-adjusted life expectancy is lower in each 
case than is life expectancy, but the difference between the disabled and non-disabled is similar 
to the unadjusted estimates.  The increase in quality-adjusted life expectancy associated with not 
being disabled is 3.7 years.   
The value of this improvement in life expectancy depends on the value of a year of life.  
Following a substantial recent literature (Viscusi and Aldy 2003), we assume that a year of life in 
good health is worth $100,000 (in 1992 dollars).   We also assume that future values are 
discounted at a 3 percent real rate of interest.  Using these assumptions, we estimate the value of 
disability prevention to be $316,000.   
These benefits need to be weighed against the cost of reducing disability.  These costs 
have two parts.  The first is the initial treatment cost that led to the reduction in disability.  To 
measure these costs, we use data on hospitalization spending for the 1989 cohort in the year after 
the CVD admission
9.  The one year interval is relatively common in studying the acute treatment 
                                                 
9 By definition all participants in the 1989 cohort had at least one CVD admissions between 1984 and 1989.  We 
averaged costs across all CVD hospitalizations for respondents with multiple relevant hospitalizations.    26 
for cardiovascular disease (Cutler and McClellan 2001; Skinner, Staiger et al. 2006).  The 
limitation to hospital costs is because only those data are reliable prior to 1991. We inflated all 
costs to a common year of 1992 using the implicit GDP Price Deflator (Economic Report of the 
President 1997). We estimate that in the year after the CVD event, hospital spending averages 
$8,610 for patients who do not receive relevant procedures and $16,332 for patients receiving 
relevant procedures. 
Although treatment costs are approximately twice as high for respondents receiving 
appropriate treatments, these costs may be offset by lower yearly spending in subsequent years 
among survivors. A previous study of 1982 and 1984 NLTCS respondents found annual per 
capita spending by Medicare for respondents without any ADL or IADL limitations was 
approximately $3,275, compared to $7,400 for respondents with at least 4 ADL and 5 IADL 
impairments and $13,100 for institutionalized respondents. These data suggest that the costs of 
intensive medical treatments that prevent or delay disability may be offset by lower annual 
average spending among healthier beneficiaries.  
More recent studies using the Medicare Current Beneficiary Survey found similar 
lifetime spending between non-disabled and disabled 70 year olds (Lubitz, Cai et al. 2003), but 
life expectancy was approximately 2.7 years longer among the non-disabled (Lubitz, Cai et al. 
2003). This provides further evidence that average annual spending may be lower among the 
non-disabled relative to the disabled. However, another recent study found spending on the non-
disabled is growing faster than spending on the disabled (Chernew, Goldman et al. 2005). 
Whether increased spending on intensive medical care treatments, such as those for 
cardiovascular disease, continues to increase life expectancy and reduce average annual yearly 
spending among the non-disabled relative to the disabled will require further investigation.    27 
 
V.  Conclusions 
Examining disability associated with cardiovascular disease leads to several important 
results.  Reduced disability associated with cardiovascular disease accounts for a significant part 
of the total reduction in disability – between 19 and 22 percent.  The evidence suggests that 
improvements in medical care, including both increased use of relevant procedures and 
pharmaceuticals, led to a significant part of this decline.  Areas with higher use experienced 
substantial reductions in mortality and disability.   
While precise data on the implications of reduced disability are lacking, the possible 
impact of disability reductions is staggering.  We estimate that preventing disability after an 
acute event can add as much as 3.7 years of quality-adjusted life expectancy, or perhaps 
$316,000 of value.  The cost of this change is much smaller.  The initial treatment costs range 
from $8,610 to $16,332, depending on procedure use.  Further, recent cost analyses reported that 
annual Medicare spending was lower for the non-disabled compared to the disabled, which 
suggests that higher treatment costs may be offset by lower future spending among a more 
healthy population.  By virtually any measure, therefore, medical technology after acute 
cardiovascular episodes is worth the cost.  
The major issue raised by our results is whether these conclusions extend to other 
conditions.  Disability reductions are complex, and will certainly involve medical as well as non-
medical factors.  Sorting these out for other conditions is a high priority for future research. 
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Note: Disability is defined as any difficulty conducting Activities of Daily Living or 
Instrumental Activities of Daily Living without help.   33 








































































































































Note: The sample is NLTCS survey respondents with at least 1 CVD hospitalization in the 5 
years prior to the survey, for all 3 survey years pooled. 
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Table 1. Most Disabling Conditions* 
Condition  % disabled   Rank 
Chronic renal failure  88.9  1 
Dementia & organic brain diseases  83.1  2 
Paralysis, Parkinsons' s, etc.  82.5  3 
Hip & pelvic fracture  80.2  4 
Acute renal failure & insufficiency  68.1  5 
Other metabolic & immunity disorders  67.0  6 
Other blood diseases  66.5  7 
Respiratory failure & insufficiency  66.5  8 
Anemia  65.9  9 
Diabetes  64.1  10 
Thyroid disorders  59.9  11 
Stroke  59.5  12 
Infectious diseases  59.2  13 
Respiratory diseases  56.8  14 
Depression  56.2  15 
Peripheral vascular disease  55.4  16 
Composite category  54.8  17 
Musculoskeletal disorders  53.2  18 
Heart failure & arrhythmia  51.5  19 
Chronic obstructive pulmonary diseases & related diseases  51.0  20 
Other mental disorders  49.9  21 
Glaucoma & cataract  48.8  22 
Hypertension  48.4  23 
Gastrointestinal disease  45.2  24 
Arthritis & arthropathy  45.0  25 
Circulatory diseases  42.0  26 
Colorectal & lung cancer  40.0  27 
Back/neck pain  39.2  28 
Ischemic heart disease  38.7  29 
Genitourinary diseases  38.7  30 
Other cancers  37.6  31 
Breast & prostate cancer  28.9  32 
* Analyses conducted using 1989 cohort, and based on primary hospitalization diagnosis codes in the proceeding 5 
years.  Composite category includes hospitalizations for any diagnoses other than the 31 specific categories above.  35 

















Note: Cross-sectional analyses based on hospitalizations in the 5 years prior to the survey. 
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Table 2: Decomposing Changes in Cardiovascular Disease Disability 
  Cohort   
  1984-1989  1989-1994  1994-1999  Change, 
1984-89 to 
1994-99 
Share with CVD event  26.5%  29.0%  26.3%  -0.2% 
Share with an event who survive  57.2  58.4  61.5  4.3 
Share of survivors who are 
disabled 
47.6  43.7  39.4  -8.2 
Source: Authors tabulations from the National Long-Term Care Survey. 
 
Note: Data are based on respondents with a CVD hospitalization in between survey waves, and known 
health status at the second survey. Weights were adjusted to the age and sex distribution of the 1999 
NLTCS survey population, and account for unknown follow-up status at the second survey.  
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Figure 4. Likelihood of reporting disability among respondents with specific cardiovascular 


















   38 
 
Table 3: Relevant Procedures for Cardiovascular Disease Admissions 
Condition  Appropriate procedures (CPT-4 Code) 
Stroke  Incision, excision, and occlusion of vessels (38) 
Hypertension  --- 
Ischemic heart disease  Operations on vessels of heart (36) 
Other operations on heart and pericardium (37) 
Heart failure and arrhythmia  Other operations on heart and pericardium (37) 
Conversion of cardiac rhythm (99) 
Peripheral vascular disease  Incision, excision, and occlusion of vessels (38) 
Operation operations on vessels (39) 
Other procedures on musculoskeletal system (84) 
Other circulatory diseases  Operations on valves and septa of heart (35) 
Other operations on heart and pericardium (37) 
Incision, excision, and occlusion of vessels (38) 
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Table 4: Average Rates of Procedures and Pharmaceuticals 
Measure  1984-1989  1989-1994  1994-1999 
Share of people receiving appropriate 
procedure, % (SD) 
21.1 (0.4)  26.1 (0.5)  34.2 (0.6) 
By specific conditions       
     Ischemic Heart Disease  22.6 (0.9)  33.2 (1.0)  47.9 (1.3) 
     Stroke  13.0 (0.8)  17.1 (0.9)  24.8 (1.0) 
     Heart Failure  11.3 (0.6)  11.9 (0.8)  14.2 (0.9) 
     Other Circulatory Diseases  29.7 (1.1)  32.5 (1.2)  43.0 (1.3) 
Beta-blockers  ---  50.7 (1.0)  --- 
Reperfusion    67.1 (0.8)   
Aspirin     76.4 (0.6)   
Ace-inhibitors    60.0 (0.6)   
 
 
Note: Based on respondents with a CVD hospitalization between survey waves. The procedure figures 
are the averages across HRRs, consistent with the CCP data.  
   40 
Table 5. Demographic characteristics of CVD cohort, by year of baseline survey* 
  1984  1989  1994 
  N = 4,146 
wN = 6,403,326 
 
N = 3,671 
wN = 7,935,884 
N = 3,676 
wN = 7,723,454 
Age groups, %       
65 – 69    20.0  21.6  21.0 
70 – 74  24.8  24.3  22.7 
75 – 79  23.2  23.4  24.0 
80 – 84    17.2  16.7  17.1 
85+   14.8  14.1  15.2 
       
Male, %  45.0  45.7  45.4 
       
Non-white, %  8.0  7.9  8.8 
       
Marital status, %       
Married  51.3  51.1  51.3 
Widowed  39.6  37.8  36.7 
Divorced, Separated 
or Single 
8.1  10.0  9.5 
Unknown marital 
status 
1.1  1.1  2.4 
       
Disabled at baseline 
survey, % 
32.2  30.0  25.9 




0.94 (0.02)  1.04 (0.02)  1.07 (0.02) 
*Estimates adjusted to the age and sex distribution of the 1999 population of Medicare beneficiaries 
**Hospitalizations for cardiovascular disease events were excluded from the Charlson index.   41 
Table 6. All CVD: Multinomial Regression Models for Health Status Outcome 5 Years 
after Baseline Survey * ** 
  Model 1:  Model 2:  
Coefficients (SEs)  Disability  Death  Disability  Death 
Year89  -0.00 (0.09)  -0.01 (0.08)  -0.00 (0.09)  0.02 (0.08) 
Year94  -0.28 (0.08)†  -0.31 (0.08)†  -0.27 (0.10)†  -0.22 (0.09)# 
Reperfusion  -  -  0.01 (0.01) #  0.00 (0.01) 
Reperfusion * 
Year89 
-  -  -0.02 (0.01)#  -0.00 (0.01) 
Reperfusion * 
Year94 
-  -  -0.03 (0.01)†  -0.01 (0.01) 
Beta Blockers  -  -  -0.00 (0.01)  0.00 (0.00) 
Beta Blocker * 
Year89 
-  -  -0.00 (0.01)  -0.01 (0.01) 
Beta Blocker * 
Year94 
-  -  -0.01 (0.01)  -0.02 (0.01)† 
Aspirin  -  -  0.00 (0.01)  0.00 (0.01) 
Aspirin * Year89  -  -  -0.01 (0.01)  -0.02 (0.01) 
Aspirin * Year94  -  -  0.00 (0.01)  -0.00 (0.01) 
Ace-inhibitors  -  -  0.01 (0.01)#  0.01 (0.01) 
Ace-inhibitor 
*Year89 
-  -  -0.01 (0.01)  -0.00 (0.01) 
Ace-inhibitor 
*Year94 
-  -  0.00 (0.01)  0.00 (0.01) 
     
Relevant procedures  -  -  -0.00 (0.00)  -0.01 (0.00)# 
     
F-tests     
Disability and Death: 
All CCP variables 
  P = 0.0008  P = 0.0203 
Overall: All CCP 
variables 
  P = 0.0025 
     
Model Statistics     
N  11491  11491 
F-test  57.27  43.54 
P-value  <0.0001  <0.0001 
*Models also adjust for age and sex interactions, marital status, race (white vs. other), Charlson co-morbidity score, 
and hospitalizations for stroke, hypertension, heart failure, peripheral vascular disease and circulatory diseases.  
**All treatment and demographic covariates were centered at their means. As a result, the coefficients on the year 
covariates in Models 1 (and 2) can be interpreted as the change in outcome for an average person (in an average 
area). 
#p<0.05 
†p<0.01   42 
Figure 5. All CVD: Change in the probability of being disabled, dead, and non-disabled, 
1994 – 1984, by 10
th and 90





















































































   43 
Figure 6. All CVD: Change in the probability of being disabled, dead, and non-disabled, 
1994 – 1984, by 10
th and 90
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 Table 7.  Stroke: Multinomial Regression Models for Health Status Outcome 5 Years after 
Baseline Survey* ** 
  Model 1:   Model 2: 
Coefficients (SEs)  Disability  Death  Disability  Death 
Year89  0.05 (0.18)  -0.04 (0.16)  0.11 (0.19)  -0.01 (0.17) 
Year94  -0.38 (0.15)#  -0.44 (0.14)†  -0.22 (0.17)  -0.34 (0.17)# 
Reperfusion  -  -  0.02 (0.01)  0.01 (0.01) 
Reperfusion*Year89  -  -  -0.02 (0.02)  -0.02 (0.02) 
Reperfusion*Year94  -  -  -0.05 (0.02) †  -0.02 (0.02) 
Beta Blockers  -  -  0.01 (0.01)  0.01 (0.01) 
Beta Blockers*Year89  -  -  -0.02 (0.02)  -0.02 (0.02) 
Beta Blockers*Year94  -  -  -0.02 (0.01)  -0.03 (0.01)# 
Aspirin  -  -  -0.02 (0.02)  -0.00 (0.02) 
Aspirin*Year89  -  -  -0.02 (0.03)  -0.06 (0.03)# 
Aspirin*Year94  -  -  0.04 (0.04)  0.01 (0.03) 
Ace-Inhibitors  -  -  0.01 (0.01)  0.01 (0.01) 
Ace-Inhibitors*Year89  -  -  0.00 (0.02)  0.00 (0.02) 
Ace-Inhibitors*Year94  -  -  -0.00 (0.02)  0.01 (0.02) 
Warfarin  -  -  -0.04 (0.02)  -0.02 (0.02) 
Warfarin*Year89  -  -  0.02 (0.04)  0.03 (0.04) 
Warfarin*Year94  -  -  0.02 (0.03)  0.01 (0.04) 
Antithrombolytics  -  -  0.03 (0.04)  -0.01 (0.04) 
Antithrombolytics*Year89  -  -  -0.02 (0.05)  0.03 (0.05) 
Antithrombolytics*Year94  -  -  -0.03 (0.04)  -0.03 (0.05) 
     
Relevant procedures  -  -  -0.01 (0.01) †  0.00 (0.01) 
     
F-tests     
     
For disability and death: 
All HRR and state 
variables  
-  0.1750  0.0008 
Overall: All HRR and 
state variables  
-  0.0003 
     
Model Statistics     
N  3355  3355 
F-test  10.06  9.04 
P-value  <0.0001  <0.0001 
*Models also adjust for age and sex interactions, marital status, race (white vs. other), Charlson co-morbidity score, 
and hospitalizations for stroke, hypertension, heart failure, peripheral vascular disease and circulatory diseases.  
**All treatment and demographic covariates were centered at their means. As a result, the coefficients on the year 
covariates in Models 1 (and 2) can be interpreted as the change in outcome for an average person (in an average 
area). 
#p<0.05 
†p<0.01   45 
Figure 8. Stroke: Change in the probability of being disabled, dead, and non-disabled, 1994 
– 1984, by 10
th and 90
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Figure 9. Stroke: Change in the probability of being disabled, dead, and non-disabled, 1994 
– 1984, by 10
th and 90

























































































   47 
Table 8. Heart Failure & Arrhythmia: Multinomial Regression Models for Health Status 
Outcome 5 Years after Baseline Survey* ** 
  Model 1:   Model 2:  
Coefficients (SEs)  Disability  Death  Disability  Death 
Year89  0.07 (0.16)  -0.10 (0.13)  0.04 (0.16)  -0.12 (0.13) 
Year94  -0.23 (0.17)  -0.39 (0.16)#  -0.25 (0.17)  -0.41 (0.14)† 
Reperfusion  -  -  -0.01 (0.01)  -0.02 (0.01) 
Reperfusion*Year89  -  -  0.01 (0.02)  0.02 (0.02) 
Reperfusion*Year94  -  -  0.01 (0.02)  0.04 (0.02)# 
Beta Blockers  -  -  -0.01 (0.01)  0.01 (0.01) 
Beta Blockers*Year89  -  -  0.01 (0.02)  -0.00 (0.01) 
Beta Blockers*Year94  -  -  -0.02 (0.02)  -0.02 (0.01) 
Aspirin  -  -  0.01 (0.02)  -0.01 (0.01) 
Aspirin*Year89  -  -  -0.02 (0.03)  -0.00 (0.03) 
Aspirin*Year94  -  -  -0.01 (0.03)  0.00 (0.02) 
Ace-Inhibitors  -  -  0.01 (0.01)  -0.01 (0.01) 
Ace-Inhibitors*Year89  -  -  0.01 (0.02)  0.01 (0.02) 
Ace-Inhibitors*Year89  -  -  0.02 (0.02)  0.03 (0.02) 
Evaluation of Ejection 
Fraction 
-  -  -0.03 (0.02)  -0.04 (0.02)# 
Eval. Ejec; Frac.* 
Year89 
-  -  -0.01 (0.03)  0.04 (0.03) 
Eval. Ejec; Frac.* 
Year94 
-  -  0.01 (0.03)  0.00 (0.03) 
     
Relevant procedures  -  -  -0.00 (0.01)  0.00 (0.01) 
     
F-tests     
For disability and 
death: All HRR and 
state variables 
-  0.0434  0.0869 
Overall: All HRR and 
state variables 
-  0.0071 
     
Model Statistics     
N  3752  3752 
F-test  17.12  12.29 
P-value  <0.0001  <0.0001 
*Models also adjust for age and sex interactions, marital status, race (white vs. other), Charlson co-morbidity score, 
and hospitalizations for stroke, hypertension, ischemic heart disease, peripheral vascular disease and circulatory 
diseases.  
**All treatment and demographic covariates were centered at their means. As a result, the coefficients on the year 
covariates in Models 1 (and 2) can be interpreted as the change in outcome for an average person (in an average 
area). 
#p<0.05 
†p<0.01   48 
Figure 9. Heart Failure & Arrhythmia: Change in the probability of being disabled, dead, 
and non-disabled, 1994 – 1984, by 10
th and 90
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Figure 10. Heart Failure & Arrhythmia: Change in the probability of being disabled, dead, 
and non-disabled, 1994 – 1984, by 10
th and 90
th percentiles of reperfusion, beta blocker, 
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 Table 9. Circulatory Diseases: Multinomial Regression Models for Health Status Outcome 
5 Years after Baseline Survey* ** 
  Model 1:  Model 2:  
Coefficients (SEs)  Disability  Death  Disability  Death 
Year89  0.11 (0.15)  0.13 (0.15)  0.10 (0.15)  0.13 (0.15) 
Year94  -0.37 (0.15)#  -0.34 (0.16)#  -0.38 (0.16)#  -0.28 (0.15) 
Reperfusion  -  -  0.02 (0.01)  0.01 (0.01) 
Reperfusion*Year89  -  -  -0.03 (0.02)  0.00 (0.02) 
Reperfusion*Year94  -  -  -0.05 (0.02)#  -0.02 (0.02) 
Beta Blockers  -  -  -0.01 (0.01)  0.01 (0.01) 
Beta Blockers*Year89  -  -  -0.02 (0.01)  -0.02 (0.01) 
Beta Blockers*Year94  -  -  -0.02 (0.01)  -0.04 (0.01) † 
Aspirin  -  -  0.00 (0.02)  -0.01 (0.02) 
Aspirin*Year89  -  -  0.01 (0.02)  0.01 (0.03) 
Aspirin*Year94  -  -  -0.00 (0.03)  0.02 (0.03) 
Ace-Inhibitors  -  -  0.01 (0.01)  0.00 (0.01) 
Ace-Inhibitors*Year89  -  -  -0.01 (0.02)  0.01 (0.02) 
Ace-Inhibitors*Year94  -  -  -0.01 (0.02)  0.00 (0.02) 
     
Relevant procedures  -  -  0.00 (0.00)  -0.00 (0.00) 
     
F-tests     
For disability and 
death: All HRR 
variables 
-  0.0435  0.1461 
Overall: All HRR 
variables 
-  0.0246 
  -   
     
Model Statistics     
N  2969  2969 
F-test  12.63  8.93 
P-value  <0.0001  <0.0001 
*Models also adjust for age and sex interactions, marital status, race (white vs. other), Charlson co-morbidity score, 
and hospitalizations for stroke, hypertension, heart failure, peripheral vascular disease and circulatory diseases.  
**All treatment and demographic covariates were centered at their means. As a result, the coefficients on the year 
covariates in Models 1 (and 2) can be interpreted as the change in outcome for an average person (in an average 
area). 
#p<0.05 
†p<0.01   51 
Figure 11. Other Circulatory Diseases: Change in the probability of being disabled, dead, 
and non-disabled, 1994 – 1984, by 10
th and 90
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Figure 12. Other Circulatory Diseases: Change in the probability of being disabled, dead, 
and non-disabled, 1994 – 1984, by 10
th and 90
th percentiles of reperfusion, beta blocker, 
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Non- Disabled  1994 
1994 
1989 
1989   54 
 
Table 10: The Persistence of Disability Status Across Surveys 
Cohort  Not Disabled 
at Baseline 
Disabled at Baseline 
1989 Cohort     
   Pr[Disabled in 1994]  31.4  79.1 
   Pr[Disabled in 1999]  36.9  72.1 
     
1994 Cohort     
   Pr[Disabled in 1999]  25.2  83.9 
Note: Disability frequencies are conditional on being alive at follow-up 




Table 11: Life Expectancy by Disability Status  
Measure  Not 
Disabled 
Disabled  Difference 
Life expectancy  7.8  5.1  2.7 
Quality adjusted life 
expectancy 
6.7  3.0  3.7 
Source: Details about the calculations are described in text.   
 
 